sibrafiban

prodrug of Ro-44-3888; structure in first source

Also Known As:

((1-(2-((4-(amino(hydroxyimino)methyl)benzoyl)amino)-1-oxopropyl)-4-piperidinyl)oxy)acetic acid ethyl ester; Ro 48-3657; Ro-48-3657; Acetic acid, 2-((1-((2S)-2-((4-((hydroxyamino)iminomethyl)benzoyl)amino)-1-oxopropyl)-4-piperidinyl)oxy)-, ethyl ester

Networked: 20 relevant articles (0 outcomes, 14 trials/studies)

Bio-Agent Context: Research Results

Experts

1.	Newby, L Kristin: 8 articles (08/2007 - 06/2002)
2.	Califf, Robert M: 7 articles (08/2007 - 06/2002)
3.	White, Harvey D: 5 articles (08/2007 - 08/2003)
4.	Bhapkar, Manjushri V: 4 articles (12/2005 - 08/2003)
5.	Armstrong, Paul W: 3 articles (08/2007 - 06/2002)
6.	Van de Werf, Frans: 3 articles (08/2007 - 08/2003)
7.	Topol, Eric J: 3 articles (06/2006 - 06/2002)
8.	Alexander, Karen P: 2 articles (08/2007 - 10/2004)
9.	Hochman, Judith S: 2 articles (08/2007 - 09/2005)
10.	SYMPHONY and 2nd SYMPHONY Investigators: 2 articles (08/2007 - 09/2004)

Related Diseases

1.	Acute Coronary Syndrome 07/01/1999 - "Pharmacokinetics and pharmacodynamics of sibrafiban, an orally administered IIb/IIIa antagonist, in patients with acute coronary syndrome." 02/03/1998 - "The Thrombolysis in Myocardial Infarction (TIMI) 12 trial was a phase II, double-blind, dose-ranging trial designed to evaluate the pharmacokinetics (PK), pharmacodynamics (PD), safety, and tolerability of sibrafiban in 329 patients after acute coronary syndromes. " 08/01/2007 - "Use of evidence-based medicine for acute coronary syndromes in the elderly and very elderly: insights from the Sibrafiban vs aspirin to Yield Maximum Protection from ischemic Heart events postacute cOroNary sYndromes trials." 10/01/2004 - "To examine the prevalence of HRT use and relationships with intermediate-term outcomes among women with ACS, we classified as HRT users or nonusers 4029 postmenopausal women (age > 50 years or postmenopausal by case report form) randomized in the Sibrafiban versus Aspirin to Yield Maximum Protection from Ischemic Heart Events Post-Acute Coronary Syndromes (SYMPHONY) and 2nd SYMPHONY trials. " 06/05/2002 - "In a prospective substudy of the Sibrafiban Versus Aspirin to Yield Maximum Protection From Ischemic Heart Events Post-acute Coronary Syndromes (SYMPHONY) trials, which randomized patients with acute coronary syndromes (ACS) to receive aspirin or sibrafiban, we measured cTnI (positive, > or =1.5 ng/ml) and CK-MB (positive, > or =7 ng/ml) in 481 patients with PCI. "
2.	Myocardial Infarction 02/03/1998 - "The Thrombolysis in Myocardial Infarction (TIMI) 12 trial was a phase II, double-blind, dose-ranging trial designed to evaluate the pharmacokinetics (PK), pharmacodynamics (PD), safety, and tolerability of sibrafiban in 329 patients after acute coronary syndromes. " 03/01/1999 - "The Thrombolysis in Myocardial Infarction (TIMI) 12 trial was a phase II, double-blind trial evaluating the effects of sibrafiban, an oral, selective antagonist of the platelet glycoprotein IIb/IIIa receptor in patients stabilized after an ACS. " 09/01/2005 - "Using 15 071 patients (normal weight [BMI = 18.5-24.9 kg/m(2)], overweight [BMI = 25-29.9 kg/m(2)], obese [BMI = 30-34.9 kg/m(2)] or very obese [BMI > or =35 kg/m(2)]) randomized from 1997-1999 in the SYMPHONY (Sibrafiban vs aspirin to Yield Maximum Protection from ischemic Heart events postacute cOroNary sYndromes) and 2nd SYMPHONY trials, we evaluated the relationships between BMI and 30-day, 90-day, and 1-year mortality and 30-day and 90-day death or myocardial infarction. "
3.	Stroke (Strokes) 09/01/2004 - "In patients stabilized after presenting with a spectrum of ACS and treated with sibrafiban and/or aspirin, stroke occurred in fewer than 1% within 90 days but carried a significant mortality and morbidity risk." 09/01/2004 - "We evaluated stroke incidence, subtypes, and outcomes, in addition to demographics and clinical risk characteristics associated with stroke among patients enrolled in the Sibrafiban versus Aspirin to Yield Maximum Protection from Ischemic Heart Events Post-acute Coronary Syndromes (SYMPHONY) and 2nd SYMPHONY trials. " 06/01/2006 - "Data from 3 trials of oral glycoprotein IIb/IIIa inhibitors (first and second Sibrafiban versus aspirin to Yield Maximum Protection from ischemic Heart events postacute cOroNary sYndromes [SYMPHONY] and Blockade of the glycoprotein IIb/IIIa Receptor to Avoid Vascular Occlusion [BRAVO]) were pooled and stroke outcomes compared among 8191 baseline statin users versus 14,752 nonusers. "
4.	Thrombosis (Thrombus) 01/01/1998 - "These properties make Ro 48-3657 an attractive candidate for evaluation in patients at high risk for arterial thrombosis." 08/01/2003 - "We studied stent thrombosis in 4,607 patients with acute coronary syndromes who received a coronary stent as part of routine care during 2 trials of aspirin versus sibrafiban for secondary prevention. "
5.	Overweight 09/01/2005 - "Using 15 071 patients (normal weight [BMI = 18.5-24.9 kg/m(2)], overweight [BMI = 25-29.9 kg/m(2)], obese [BMI = 30-34.9 kg/m(2)] or very obese [BMI > or =35 kg/m(2)]) randomized from 1997-1999 in the SYMPHONY (Sibrafiban vs aspirin to Yield Maximum Protection from ischemic Heart events postacute cOroNary sYndromes) and 2nd SYMPHONY trials, we evaluated the relationships between BMI and 30-day, 90-day, and 1-year mortality and 30-day and 90-day death or myocardial infarction. "

Related Drugs and Biologics

1.	Aspirin (Acetylsalicylic Acid)
2.	Platelet Membrane Glycoproteins
3.	Glycoproteins (Glycoprotein)
4.	Peptidomimetics
5.	Platelet Membrane Glycoprotein IIb
6.	Hydroxymethylglutaryl-CoA Reductase Inhibitors (HMG-CoA Reductase Inhibitors)
7.	tetrachloroisophthalonitrile (Bravo)
8.	orbofiban
9.	MB Form Creatine Kinase
10.	Therapeutic Uses

Related Therapies and Procedures

1.	Secondary Prevention
2.	Stents